INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic(TM) in Advanced Wound Care

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...

PepsiCo (PEP) is in the crosshairs of weight loss drugs

Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith ...
Morningstar

RION Engages Lonza to Scale Manufacturing Exosome Based Therapeutics

Lonza to support cGMP manufacturing of RION’s Purified Exosome Product™ (PEP™), a platelet-derived exosome-based drug candidate for chronic wound care and tissue regeneration Collaboration leverages ...

INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care

INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, ...